Integrative cancer care merges conventional treatments like chemotherapy and surgery with research-based traditional medicine ...

Ovarian cancer continues to pose a significant challenge in the medical field, remaining one of the leading causes of death ...

A discovery of how to target mutated proteins in tumors made a decade ago never matured into a surefire way of destroying ...

OnCusp Therapeutics receives US FDA fast track designation for CUSP06 for treatment of platinum-resistant ovarian cancer: Princeton, New Jersey Saturday, February 15, 2025, 15:00 ...

Alphamab Oncology has dosed the first subject in the randomised Phase III JSKN003-306 trial of its anti-human epidermal ...

The Union Health Ministry has begun setting up 200 daycare cancer centres in over 750 district hospitals in the country, a ...

Was it simply a fluke that he kept treating strikingly young patients? Or was his practice one tiny data point in a larger trend? He found his answer after sifting through national health data: ...

Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the Phase III clinical study (Study ID: JSKN003-306) of anti-HER2 biparatopic antibody-drug ...

Margaret McCaul spent her life savings to fund the procedure, because of a “postcode lottery” for treatment in Scotland, ...

Advanced Ovarian Cancer Pipeline Insights LAS VEGAS, NV, UNITED STATES, February 12, 2025 /EINPresswire / -- As per DelveInsight's assessme ...

Bianca Balti was pictured flashing a radiant smile as she left a press conference during the Sanremo Music Festival in Italy on Wednesday, amid her cancer battle.

"We are extremely pleased that the FDA granted Fast Track Designation to CUSP06," said Eric Slosberg, PhD, Chief Development Officer of OnCusp Therapeutics. "The early results from our Phase 1 trial ...